{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:33:34Z","timestamp":1791250414295,"version":"4.1.0"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/2.0"},{"start":{"date-parts":[[2007,10,3]],"date-time":"2007-10-03T00:00:00Z","timestamp":1191369600000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/2.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin. Exper.Med."],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.1007\/s10238-007-0134-y","type":"journal-article","created":{"date-parts":[[2007,10,19]],"date-time":"2007-10-19T12:50:03Z","timestamp":1192798203000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["New therapies in multiple myeloma"],"prefix":"10.1007","volume":"7","author":[{"given":"F.","family":"Merchionne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Perosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Dammacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,10,3]]},"reference":[{"key":"134_CR1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0889-8588(18)30341-1","volume":"6","author":"D.A. Riedel","year":"1992","unstructured":"Riedel DA, Pottern LM (1992) The epidemiology of multiple myeloma. Hematol Oncol Clin North Am 6:225","journal-title":"Hematol Oncol Clin North Am"},{"key":"134_CR2","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1056\/NEJMra041875","volume":"351","author":"R.A. Kyle","year":"2004","unstructured":"Kyle RA, Rajkumar SV (2004) Multiple myeloma. N Engl J Med 351:1860\u20131873","journal-title":"N Engl J Med"},{"key":"134_CR3","first-page":"5s","volume":"16","author":"F. Dammacco","year":"2001","unstructured":"Dammacco F, Perosa F, Procaccio P et al (2001) Mieloma multiplo e gammapatie monoclonali: quadri clinici, acquisizioni eziopatogenetiche e progressi terapeutici. Atti 102\u00b0 Congr Naz Soc Ital Med Int. Annali Italiani di Medicina Interna 16:5s\u201340s","journal-title":"Annali Italiani di Medicina Interna"},{"key":"134_CR4","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa032290","volume":"349","author":"M. Attal","year":"2003","unstructured":"Attal M, Harousseau JL, Facon T et al (2003) Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349:2495\u20132502","journal-title":"N Engl J Med"},{"key":"134_CR5","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1056\/NEJMoa022340","volume":"348","author":"J.A. Child","year":"2003","unstructured":"Child JA, Morgan GJ, Davies FE et al (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348:1875\u20131883","journal-title":"N Engl J Med"},{"key":"134_CR6","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.V87.3.1104.bloodjournal8731104","volume":"87","author":"D. Chauhan","year":"1996","unstructured":"Chauhan D, Uchiyama H, Akbarali Y et al (1996) Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 87:1104\u20131112","journal-title":"Blood"},{"key":"134_CR7","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1182\/blood.V98.2.428","volume":"98","author":"K. Podar","year":"2001","unstructured":"Podar K, Tai YT, Davies FE et al (2001) Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 98:428\u2013435","journal-title":"Blood"},{"key":"134_CR8","doi-asserted-by":"publisher","first-page":"16639","DOI":"10.1074\/jbc.M200360200","volume":"277","author":"T. Hideshima","year":"2002","unstructured":"Hideshima T, Chauhan D, Richardson P et al (2002) NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 277:16639\u201316647","journal-title":"J Biol Chem"},{"key":"134_CR9","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1046\/j.1365-2141.2002.03257.x","volume":"116","author":"S. Yaccoby","year":"2002","unstructured":"Yaccoby S, Pearse RN, Johnson CL et al (2002) Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 116:278\u2013290","journal-title":"Br J Haematol"},{"key":"134_CR10","doi-asserted-by":"publisher","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","volume":"91","author":"R.J. D\u2019Amato","year":"1994","unstructured":"D\u2019Amato RJ, Loughnan MS, Flynn E, Folkman J (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 91:4082\u20134085","journal-title":"Proc Natl Acad Sci U S A"},{"key":"134_CR11","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1006\/exer.1997.0292","volume":"64","author":"B.M. Kenyon","year":"1997","unstructured":"Kenyon BM, Browne F, D\u2019Amato RJ (1997) Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 64:971\u2013978","journal-title":"Exp Eye Res"},{"key":"134_CR12","doi-asserted-by":"publisher","first-page":"5334","DOI":"10.1200\/JCO.2005.03.723","volume":"23","author":"A. Vacca","year":"2005","unstructured":"Vacca A, Scavelli C, Montefusco V et al (2005) Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. J Clin Oncol 23:5334\u20135346","journal-title":"J Clin Oncol"},{"key":"134_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/sj.leu.2402745","volume":"17","author":"S. Lentzsch","year":"2003","unstructured":"Lentzsch S, LeBlanc R, Podar K et al (2003) Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia 17:41\u201344","journal-title":"Leukemia"},{"key":"134_CR14","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/sj.leu.2403285","volume":"18","author":"S. Kumar","year":"2004","unstructured":"Kumar S, Witzig TE, Dispenzieri A et al (2004) Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. Leukemia 18:624\u2013627","journal-title":"Leukemia"},{"key":"134_CR15","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1046\/j.1365-2141.2001.03142.x","volume":"115","author":"K. Neben","year":"2001","unstructured":"Neben K, Moehler T, Kraemer A et al (2001) Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. Br J Haematol 115:605\u2013608","journal-title":"Br J Haematol"},{"key":"134_CR16","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood.V96.9.2943","volume":"96","author":"T. Hideshima","year":"2000","unstructured":"Hideshima T, Chauhan D, Shima Y et al (2000) Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96:2943\u20132950","journal-title":"Blood"},{"key":"134_CR17","doi-asserted-by":"publisher","first-page":"4525","DOI":"10.1182\/blood.V99.12.4525","volume":"99","author":"N. Mitsiades","year":"2002","unstructured":"Mitsiades N, Mitsiades CS, Poulaki V et al (2002) Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 99:4525\u20134530","journal-title":"Blood"},{"key":"134_CR18","doi-asserted-by":"publisher","first-page":"4519","DOI":"10.1038\/sj.onc.1204623","volume":"20","author":"T. Hideshima","year":"2001","unstructured":"Hideshima T, Chauhan D, Schlossman R et al (2001) The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 20:4519\u20134527","journal-title":"Oncogene"},{"key":"134_CR19","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1084\/jem.177.6.1675","volume":"177","author":"A.L. Moreira","year":"1993","unstructured":"Moreira AL, Sampaio EP, Zmuidzinas A et al (1993) Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 177:1675\u20131680","journal-title":"J Exp Med"},{"key":"134_CR20","doi-asserted-by":"publisher","first-page":"7552","DOI":"10.1073\/pnas.93.15.7552","volume":"93","author":"B.E. Turk","year":"1996","unstructured":"Turk BE, Jiang H, Liu JO (1996) Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production. Proc Natl Acad Sci U S A 93:7552\u20137556","journal-title":"Proc Natl Acad Sci U S A"},{"key":"134_CR21","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/0162-3109(95)00050-X","volume":"31","author":"H. Geitz","year":"1996","unstructured":"Geitz H, Handt S, Zwingenberger K (1996) Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 31:213\u2013221","journal-title":"Immunopharmacology"},{"key":"134_CR22","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1038\/sj.leu.2402295","volume":"15","author":"D. Gupta","year":"2001","unstructured":"Gupta D, Treon SP, Shima Y et al (2001) Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15:1950\u20131961","journal-title":"Leukemia"},{"key":"134_CR23","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1084\/jem.187.11.1885","volume":"187","author":"P.A. Haslett","year":"1998","unstructured":"Haslett PA, Corral LG, Albert M, Kaplan G (1998) Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 187:1885\u20131892","journal-title":"J Exp Med"},{"key":"134_CR24","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1182\/blood.V98.1.210","volume":"98","author":"F.E. Davies","year":"2001","unstructured":"Davies FE, Raje N, Hideshima T et al (2001) Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98:210\u2013216","journal-title":"Blood"},{"key":"134_CR25","doi-asserted-by":"publisher","first-page":"5673","DOI":"10.1038\/sj.onc.1205664","volume":"21","author":"C.S. Mitsiades","year":"2002","unstructured":"Mitsiades CS, Mitsiades N, Poulaki V et al (2002) Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1\/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 21:5673\u20135683","journal-title":"Oncogene"},{"key":"134_CR26","doi-asserted-by":"publisher","first-page":"22382","DOI":"10.1074\/jbc.M100938200","volume":"276","author":"J.A. Keifer","year":"2001","unstructured":"Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS Jr (2001) Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 276:22382\u201322387","journal-title":"J Biol Chem"},{"key":"134_CR27","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1046\/j.1365-2141.2003.04605.x","volume":"123","author":"M.A. Thompson","year":"2003","unstructured":"Thompson MA, Witzig TE, Kumar S et al (2003) Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma. Br J Haematol 123:305\u2013308","journal-title":"Br J Haematol"},{"key":"134_CR28","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1182\/blood.V100.6.2263","volume":"100","author":"K. Neben","year":"2002","unstructured":"Neben K, Mytilineos J, Moehler TM et al (2002) Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. Blood 100:2263\u20132265","journal-title":"Blood"},{"key":"134_CR29","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","volume":"341","author":"S. Singhal","year":"1999","unstructured":"Singhal S, Mehta J, Desikan R et al (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565\u20131571","journal-title":"N Engl J Med"},{"key":"134_CR30","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1182\/blood.V98.2.492","volume":"98","author":"B. Barlogie","year":"2001","unstructured":"Barlogie B, Desikan R, Eddlemon P et al (2001) Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 98:492\u2013494","journal-title":"Blood"},{"key":"134_CR31","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/sj.thj.6200175","volume":"3","author":"I. Yakoub-Agha","year":"2002","unstructured":"Yakoub-Agha I, Attal M, Dumontet C et al (2002) Thalidomide in patients with advanced multiple myeloma: a study of 83 patients - report of the Intergroupe Francophone du Myelome (IFM). Hematol J 3:185\u2013192","journal-title":"Hematol J"},{"key":"134_CR32","first-page":"399","volume":"86","author":"A. Palumbo","year":"2001","unstructured":"Palumbo A, Giaccone L, Bertola A et al (2001) Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica 86:399\u2013403","journal-title":"Haematologica"},{"key":"134_CR33","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1023\/A:1011132808904","volume":"12","author":"M.A. Dimopoulos","year":"2001","unstructured":"Dimopoulos MA, Zervas K, Kouvatseas G et al (2001) Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 12:991\u2013995","journal-title":"Ann Oncol"},{"key":"134_CR34","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/sj.leu.2403322","volume":"18","author":"R. Garcia-Sanz","year":"2004","unstructured":"Garcia-Sanz R, Gonzalez-Porras JR, Hernandez JM et al (2004) The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed\/refractory multiple myeloma. Leukemia 18:856\u2013863","journal-title":"Leukemia"},{"key":"134_CR35","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/j.1365-2141.2005.05521.x","volume":"129","author":"C. Kyriakou","year":"2005","unstructured":"Kyriakou C, Thomson K, D\u2019sa S et al (2005) Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. Br J Haematol 129:763\u2013770","journal-title":"Br J Haematol"},{"key":"134_CR36","first-page":"133","volume":"91","author":"M. Offidani","year":"2006","unstructured":"Offidani M, Corvatta L, Marconi M et al (2006) Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed\/refractory multiple myeloma: a prospective, multicenter, phase II study. Haematologica 91:133\u2013136","journal-title":"Haematologica"},{"key":"134_CR37","first-page":"408","volume":"87","author":"P. Tosi","year":"2002","unstructured":"Tosi P, Zamagni E, Cellini C et al (2002) Salvage therapy with thalidomide in patients with advanced relapsed\/refractory multiple myeloma. Haematologica 87:408\u2013414","journal-title":"Haematologica"},{"key":"134_CR38","doi-asserted-by":"publisher","first-page":"875","DOI":"10.4065\/79.7.875","volume":"79","author":"P. Richardson","year":"2004","unstructured":"Richardson P, Schlossman R, Jagannath S et al (2004) Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc 79:875\u2013882","journal-title":"Mayo Clin Proc"},{"key":"134_CR39","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/sj.leu.2403539","volume":"19","author":"K.L. Wu","year":"2005","unstructured":"Wu KL, Helgason HH, van der Holt B et al (2005) Analysis of efficacy and toxicity of thalidomide in 122 patients with multiple myeloma: response of soft-tissue plasmacytomas. Leukemia 19:143\u2013145","journal-title":"Leukemia"},{"key":"134_CR40","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1046\/j.1365-2141.2003.04345.x","volume":"121","author":"A. Anagnostopoulos","year":"2003","unstructured":"Anagnostopoulos A, Weber D, Rankin K et al (2003) Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 121:768\u2013771","journal-title":"Br J Haematol"},{"key":"134_CR41","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1053\/j.seminhematol.2003.09.006","volume":"40","author":"R. Alexanian","year":"2003","unstructured":"Alexanian R, Weber D, Anagnostopoulos A et al (2003) Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma. Semin Hematol 40:3\u20137","journal-title":"Semin Hematol"},{"key":"134_CR42","doi-asserted-by":"publisher","first-page":"889","DOI":"10.4065\/81.7.889","volume":"81","author":"M.A. Hussein","year":"2006","unstructured":"Hussein MA, Baz R, Srkalovic G et al (2006) Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma. Mayo Clin Proc 81:889\u2013895","journal-title":"Mayo Clin Proc"},{"key":"134_CR43","doi-asserted-by":"publisher","first-page":"4319","DOI":"10.1200\/JCO.2002.02.116","volume":"20","author":"S.V. Rajkumar","year":"2002","unstructured":"Rajkumar SV, Hayman S, Gertz MA et al (2002) Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 20:4319\u20134323","journal-title":"J Clin Oncol"},{"key":"134_CR44","first-page":"826","volume":"89","author":"M. Cavo","year":"2004","unstructured":"Cavo M, Zamagni E, Tosi P et al (2004) First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 89:826\u2013831","journal-title":"Haematologica"},{"key":"134_CR45","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/ajh.2830330203","volume":"33","author":"R. Alexanian","year":"1990","unstructured":"Alexanian R, Barlogie B, Tucker S (1990) VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 33:86\u201389","journal-title":"Am J Hematol"},{"key":"134_CR46","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1182\/blood-2005-02-0522","volume":"106","author":"M. Cavo","year":"2005","unstructured":"Cavo M, Zamagni E, Tosi P et al (2005) Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 106:35\u201339","journal-title":"Blood"},{"key":"134_CR47","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1056\/NEJMoa053583","volume":"354","author":"B. Barlogie","year":"2006","unstructured":"Barlogie B, Tricot G, Anaissie E et al (2006) Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 354:1021\u20131030","journal-title":"N Engl J Med"},{"key":"134_CR48","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","volume":"24","author":"S.V. Rajkumar","year":"2006","unstructured":"Rajkumar SV, Blood E, Vesole D et al (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24:431\u2013436","journal-title":"J Clin Oncol"},{"key":"134_CR49","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","volume":"367","author":"A. Palumbo","year":"2006","unstructured":"Palumbo A, Bringhen S, Caravita T et al (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367:825\u2013831","journal-title":"Lancet"},{"key":"134_CR50","first-page":"252","volume":"91","author":"M.A. Dimopoulos","year":"2006","unstructured":"Dimopoulos MA, Anagnostopoulos A, Terpos E et al (2006) Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma. Haematologica 91:252\u2013254","journal-title":"Haematologica"},{"key":"134_CR51","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","volume":"108","author":"M. Attal","year":"2006","unstructured":"Attal M, Harousseau JL, Leyvraz S et al (2006) Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108:3289\u20133294","journal-title":"Blood"},{"key":"134_CR52","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1002\/cncr.21852","volume":"106","author":"B.T. Brinker","year":"2006","unstructured":"Brinker BT, Waller EK, Leong T et al (2006) Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma. Cancer 106:2171\u20132180","journal-title":"Cancer"},{"key":"134_CR53","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1093\/annonc\/mdf188","volume":"13","author":"R. Alexanian","year":"2002","unstructured":"Alexanian R, Weber D, Giralt S, Delasalle K (2002) Consolidation therapy of multiple myeloma with thalidomidedexamethasone after intensive chemotherapy. Ann Oncol 13:1116\u20131119","journal-title":"Ann Oncol"},{"key":"134_CR54","doi-asserted-by":"publisher","first-page":"8170","DOI":"10.1158\/1078-0432.CCR-04-1106","volume":"10","author":"A.K. Stewart","year":"2004","unstructured":"Stewart AK, Chen CI, Howson-Jan K et al (2004) Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant. Clin Cancer Res 10:8170\u20138176","journal-title":"Clin Cancer Res"},{"key":"134_CR55","first-page":"2615","volume":"59","author":"J. Adams","year":"1999","unstructured":"Adams J, Palombella VJ, Sausville EA et al (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59:2615\u20132622","journal-title":"Cancer Res"},{"key":"134_CR56","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1182\/blood-2002-08-2543","volume":"101","author":"T. Hideshima","year":"2003","unstructured":"Hideshima T, Mitsiades C, Akiyama M et al (2003) Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 101:1530\u20131534","journal-title":"Blood"},{"key":"134_CR57","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1200\/JCO.2005.11.030","volume":"23","author":"S.V. Rajkumar","year":"2005","unstructured":"Rajkumar SV, Richardson PG, Hideshima T, Anderson KC (2005) Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 23:630\u2013639","journal-title":"J Clin Oncol"},{"key":"134_CR58","first-page":"3071","volume":"61","author":"T. Hideshima","year":"2001","unstructured":"Hideshima T, Richardson P, Chauhan D et al (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071\u20133076","journal-title":"Cancer Res"},{"key":"134_CR59","doi-asserted-by":"publisher","first-page":"8386","DOI":"10.1038\/sj.onc.1207170","volume":"22","author":"T. Hideshima","year":"2003","unstructured":"Hideshima T, Chauhan D, Hayashi T et al (2003) Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene 22:8386\u20138393","journal-title":"Oncogene"},{"key":"134_CR60","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1158\/0008-5472.CAN-05-1195","volume":"66","author":"A.M. Roccaro","year":"2006","unstructured":"Roccaro AM, Hideshima T, Raje N et al (2006) Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 66:184\u2013191","journal-title":"Cancer Res"},{"key":"134_CR61","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/sj.leu.2403758","volume":"19","author":"C. Shimazaki","year":"2005","unstructured":"Shimazaki C, Uchida R, Nakano S et al (2005) High serum bone-specific alkaline phosphatase level after bortezomibcombined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation. Leukemia 19:1102\u20131103","journal-title":"Leukemia"},{"key":"134_CR62","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.1600-0609.2006.00692.x","volume":"77","author":"U. Heider","year":"2006","unstructured":"Heider U, Kaiser M, Muller C et al (2006) Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur J Haematol 77:233\u2013238","journal-title":"Eur J Haematol"},{"key":"134_CR63","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3816\/CLM.2006.n.047","volume":"7","author":"M. Zangari","year":"2006","unstructured":"Zangari M, Yaccoby S, Cavallo F et al (2006) Response to bortezomib and activation of osteoblasts in multiple myeloma. Clin Lymphoma Myeloma 7:109\u2013114","journal-title":"Clin Lymphoma Myeloma"},{"key":"134_CR64","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1182\/blood-2006-11-059188","volume":"110","author":"N. Giuliani","year":"2007","unstructured":"Giuliani N, Morandi F, Tagliaferri S et al (2007) The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 110:334\u2013338","journal-title":"Blood"},{"key":"134_CR65","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1056\/NEJMoa030288","volume":"348","author":"P.G. Richardson","year":"2003","unstructured":"Richardson PG, Barlogie B, Berenson J et al (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609\u20132617","journal-title":"N Engl J Med"},{"key":"134_CR66","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/j.1365-2141.2004.05188.x","volume":"127","author":"S. Jagannath","year":"2004","unstructured":"Jagannath S, Barlogie B, Berenson J et al (2004) A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127:165\u2013172","journal-title":"Br J Haematol"},{"key":"134_CR67","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"P.G. Richardson","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW et al (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487\u20132498","journal-title":"N Engl J Med"},{"key":"134_CR68","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1200\/JCO.2005.03.2383","volume":"24","author":"J.R. Berenson","year":"2006","unstructured":"Berenson JR, Yang HH, Sadler K et al (2006) Phase I\/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 24:937\u2013944","journal-title":"J Clin Oncol"},{"key":"134_CR69","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1182\/blood-2006-08-042275","volume":"109","author":"A. Palumbo","year":"2007","unstructured":"Palumbo A, Ambrosini MT, Benevolo G et al (2007) Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood 109:2767\u20132772","journal-title":"Blood"},{"key":"134_CR70","first-page":"2547","volume":"106","author":"P.G. Richardson","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW et al (2005) Bortezomib continues to demonstrate superior efficacy compared with high-dose dexamethasone in relapsed multiple myeloma: updated results of the APEX trial. Blood (ASH Annual Meeting Abstracts) 106:2547","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"134_CR71","first-page":"929","volume":"91","author":"S. Jagannath","year":"2006","unstructured":"Jagannath S, Richardson PG, Barlogie B et al (2006) Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and\/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 91:929\u2013934","journal-title":"Haematologica"},{"key":"134_CR72","first-page":"2555","volume":"106","author":"R. Popat","year":"2005","unstructured":"Popat R, Oakervee HE, Foot N et al (2005) A phase I\/II study of bortezomib and low dose intravenous melphalan (BM) for relapsed multiple myeloma. Blood (ASH Annual Meeting Abstracts) 106:2555","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"134_CR73","first-page":"3537","volume":"108","author":"F.E. Davies","year":"2006","unstructured":"Davies FE, Wu P, Srikanth M et al (2006) The combination of Cyclophosphamide, Velcade and Dexamethasone (CVD) induces high response rates with minimal toxicity compared to Velcade alone (V) and Velcade plus Dexamethasone. Blood (ASH Annual Meeting Abstracts) 108:3537","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"134_CR74","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1182\/blood-2004-07-2911","volume":"105","author":"R.Z. Orlowski","year":"2005","unstructured":"Orlowski RZ, Voorhees PM, Garcia RA et al (2005) Phase I trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 105:3058\u20133065","journal-title":"Blood"},{"key":"134_CR75","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s00277-006-0220-3","volume":"86","author":"S.E. Biehn","year":"2007","unstructured":"Biehn SE, Moore DT, Voorhees PM et al (2007) Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin. Ann Hematol 86:211\u2013216","journal-title":"Ann Hematol"},{"key":"134_CR76","first-page":"404","volume":"108","author":"R.Z. Orlowski","year":"2006","unstructured":"Orlowski RZ, Zhuang SH, Parekh T et al, the DOXIL-MMY-3001 Study Investigators (2006) The combination of pegylated liposomal doxorubicin and bortezomib significantly improves time to progression of patients with relapsed\/refractory multiple myeloma compared with bortezomib alone: results from a planned interim analysis of a randomized phase III study. Blood (ASH Annual Meeting Abstracts) 108:404","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"134_CR77","first-page":"3539","volume":"108","author":"A.A. Chanan-khan","year":"2006","unstructured":"Chanan-khan AA, Padmanabhan S, Miller KC et al (2006) Final results of a phase II study of bortezomib (Velcade) in combination with liposomal doxorubicin (Doxi) and thalidomide (VDT) demonstrate a sustained high response rates in patients (pts) with relapsed (rel) or refractory (ref) multiple myeloma. Blood (ASH Annual Meeting Abstracts) 108:3539","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"134_CR78","first-page":"2552","volume":"106","author":"M. Zangari","year":"2006","unstructured":"Zangari M, Barlogie B, Burns MJ et al (2006) Velcade (V)-Thalidomide (T)-Dexamethasone (D) for advanced and refractory multiple myeloma (MM): long term follow-up of phase I\/II trial UARK 2001\u201337: superior outcome in patients with normal cytogenetics and no prior T. Blood (ASH Annual Meeting Abstracts) 106:2552","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"134_CR79","first-page":"405","volume":"108","author":"P.G. Richardson","year":"2006","unstructured":"Richardson PG, Jagannath S, Avigan DE et al (2006) Lenalidomide plus bortezomib (Rev-Vel) in relapsed and\/or refractory multiple myeloma (MM): final results of a multicenter phase 1 trial. Blood (ASH Annual Meeting Abstracts) 108:405","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"134_CR80","first-page":"2548","volume":"106","author":"P.G. Richardson","year":"2005","unstructured":"Richardson PG, Chanan-khan AA, Schlossman R et al (2005) A multicenter phase II trial of bortezomib in patients with previously untreated multiple myeloma: efficacy with manageable toxicity in patients with unexpectedly high rates of baseline peripheral neuropathy. Blood (ASH Annual Meeting Abstracts) 106:2548","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"134_CR81","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1182\/blood-2006-04-019778","volume":"108","author":"M.V. Mateos","year":"2006","unstructured":"Mateos MV, Hernandez JM, Hernandez MT et al (2006) Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1\/2 study. Blood 108:2165\u20132172","journal-title":"Blood"},{"key":"134_CR82","first-page":"1498","volume":"91","author":"J.L. Harousseau","year":"2006","unstructured":"Harousseau JL, Attal M, Leleu X et al (2006) Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 91:1498\u20131505","journal-title":"Haematologica"},{"key":"134_CR83","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/j.1365-2141.2005.05540.x","volume":"129","author":"S. Jagannath","year":"2005","unstructured":"Jagannath S, Durie BG, Wolf J et al (2005) Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 129:776\u2013783","journal-title":"Br J Haematol"},{"key":"134_CR84","first-page":"56","volume":"108","author":"J.L. Harousseau","year":"2006","unstructured":"Harousseau JL, Marit G, Caillot D et al (2006) VEL-CADE\/Dexamethasone (Vel\/Dex) versus VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): an interim analysis of the IFM 2005\u201301 randomized multicenter phase III trial. Blood (ASH Annual Meeting Abstracts) 108:56","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"134_CR85","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/j.1365-2141.2005.05519.x","volume":"129","author":"H.E. Oakervee","year":"2005","unstructured":"Oakervee HE, Popat R, Curry N et al (2005) PAD combination therapy (PS-341\/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 129:755\u2013762","journal-title":"Br J Haematol"},{"key":"134_CR86","first-page":"3538","volume":"108","author":"B.A. Di Carlo","year":"2006","unstructured":"Di Carlo BA, Stern JL, Schuster M et al (2006) Breaking the plateau response in myeloma: preliminary results of a phase II pilot study of sequential bortezomib in combination with dexamethasone and pegylated liposomal doxorubicin (DoVeD) in patients no longer responsive to standard induction regimens. Blood (ASH Annual Meeting Abstracts) 108:3538","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"134_CR87","first-page":"797","volume":"108","author":"R.Z. Orlowski","year":"2006","unstructured":"Orlowski RZ, Peterson BL, Sanford B et al; the Cancer and Leukemia Group B (2006) Bortezomib and pegylated liposomal doxorubicin as induction therapy for adult patients with symptomatic multiple myeloma: Cancer and Leukemia Group B Study 10301. Blood (ASH Annual Meeting Abstracts) 108:797","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"134_CR88","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S0093-7754(01)90033-8","volume":"28","author":"T. Hideshima","year":"2001","unstructured":"Hideshima T, Chauhan D, Podar K et al (2001) Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol 28:607\u2013612","journal-title":"Semin Oncol"},{"key":"134_CR89","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1038\/sj.bjc.6600607","volume":"87","author":"K. Dredge","year":"2002","unstructured":"Dredge K, Marriott JB, Macdonald CD et al (2002) Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 87:1166\u20131172","journal-title":"Br J Cancer"},{"key":"134_CR90","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1182\/blood-2002-03-0996","volume":"100","author":"P.G. Richardson","year":"2002","unstructured":"Richardson PG, Schlossman RL, Weller E et al (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100:3063\u20133067","journal-title":"Blood"},{"key":"134_CR91","doi-asserted-by":"publisher","first-page":"3458","DOI":"10.1182\/blood-2006-04-015909","volume":"108","author":"P.G. Richardson","year":"2006","unstructured":"Richardson PG, Blood E, Mitsiades CS et al (2006) A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 108:3458\u20133464","journal-title":"Blood"},{"key":"134_CR92","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1093\/annonc\/mdl313","volume":"17","author":"R. Baz","year":"2006","unstructured":"Baz R, Walker E, Karam MA et al (2006) Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol 17:1766\u20131771","journal-title":"Ann Oncol"},{"key":"134_CR93","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1365-2141.2007.06538.x","volume":"137","author":"G.J. Morgan","year":"2007","unstructured":"Morgan GJ, Schey SA, Wu P et al (2007) Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. Br J Haematol 137:268\u2013269","journal-title":"Br J Haematol"},{"key":"134_CR94","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1182\/blood-2005-07-2817","volume":"106","author":"S.V. Rajkumar","year":"2005","unstructured":"Rajkumar SV, Hayman SR, Lacy MQ et al (2005) Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma. Blood 106:4050\u20134053","journal-title":"Blood"},{"key":"134_CR95","first-page":"6","volume":"106","author":"M.A. Dimopoulos","year":"2005","unstructured":"Dimopoulos MA, Spencer T, Attal M et al (2005) Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): results of a phase 3 study (MM-010). Blood (ASH Annual Meeting Abstracts) 106:6","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"134_CR96","first-page":"3547","volume":"108","author":"D. Weber","year":"2006","unstructured":"Weber D, Wang M, Chen CI et al (2006) Lenalidomide plus high dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of 2 phase III studies (MM-009, MM-010) and subgroup analysis of patients with impaired renal function. Blood (ASH Annual Meeting Abstracts) 108:3547","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"134_CR97","first-page":"800","volume":"108","author":"A. Palumbo","year":"2006","unstructured":"Palumbo A, Falco P, Falcone A et al (2006) Oral Revlimid\u00ae plus Melphalan and Prednisone (R-MP) for newly diagnosed multiple myeloma: results of a multicenter phase I\/II study. Blood (ASH Annual Meeting Abstracts) 108:800","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"134_CR98","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1212\/01.WNL.0000037480.59194.85","volume":"59","author":"V. Chaudhry","year":"2002","unstructured":"Chaudhry V, Cornblath DR, Corse A et al (2002) Thalidomide-induce neuropathy. Neurology 59:1872\u20131875","journal-title":"Neurology"},{"key":"134_CR99","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S0002-9343(02)01300-1","volume":"113","author":"C.L. Bennett","year":"2002","unstructured":"Bennett CL, Schumock GT, Desai AA et al (2002) Thalidomide-associated deep vein thrombosis and pulmonary embolism. Am J Med 113:603\u2013606","journal-title":"Am J Med"},{"key":"134_CR100","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1182\/blood-2002-06-1674","volume":"100","author":"M. Cavo","year":"2002","unstructured":"Cavo M, Zamagni E, Cellini C et al (2002) Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Blood 100:2272\u20132273","journal-title":"Blood"},{"key":"134_CR101","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1056\/NEJM200106213442516","volume":"344","author":"K. Osman","year":"2001","unstructured":"Osman K, Comenzo R, Rajkumar SV (2001) Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med 344:1951\u20131952","journal-title":"N Engl J Med"},{"key":"134_CR102","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.1200\/JCO.2006.05.6689","volume":"24","author":"L. Mileshkin","year":"2006","unstructured":"Mileshkin L, Stark R, Day B et al (2006) Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 24:4507\u20134514","journal-title":"J Clin Oncol"},{"key":"134_CR103","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1212\/WNL.62.12.2291","volume":"62","author":"G. Cavaletti","year":"2004","unstructured":"Cavaletti G, Beronio A, Reni L et al (2004) Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study. Neurology 62:2291\u20132293","journal-title":"Neurology"},{"key":"134_CR104","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/j.1600-0609.2004.00382.x","volume":"74","author":"P. Tosi","year":"2005","unstructured":"Tosi P, Zamagni E, Cellini C et al (2005) Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. Eur J Haematol 74:212\u2013216","journal-title":"Eur J Haematol"},{"key":"134_CR105","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.4065\/80.12.1549","volume":"80","author":"S.V. Rajkumar","year":"2005","unstructured":"Rajkumar SV (2005) Thalidomide therapy and deep venous thrombosis in multiple myeloma. Mayo Clin Proc 80:1549\u20131551","journal-title":"Mayo Clin Proc"},{"key":"134_CR106","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1056\/NEJMc053530","volume":"354","author":"S.V. Rajkumar","year":"2006","unstructured":"Rajkumar SV, Blood E (2006) Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 354:2079\u20132080","journal-title":"N Engl J Med"},{"issue":"[Suppl2]","key":"134_CR107","first-page":"160","volume":"90","author":"M.A. Dimopoulos","year":"2005","unstructured":"Dimopoulos MA, Weber D, Chen CI (2005) Evaluating oral lenalidomide (Revlimid) and dexamethasone versus placebo and dexamethasone in patients with relapsed or refractory multiple myeloma. Haematologica 90[Suppl 2]:160","journal-title":"Haematologica"},{"key":"134_CR108","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1111\/j.1538-7836.2006.02059.x","volume":"4","author":"A. Palumbo","year":"2006","unstructured":"Palumbo A, Rus C, Zeldis JB et al (2006) Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide. J Thromb Haemost 4:1842\u20131845","journal-title":"J Thromb Haemost"},{"key":"134_CR109","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1200\/JCO.2005.04.7779","volume":"24","author":"P.G. Richardson","year":"2006","unstructured":"Richardson PG, Briemberg H, Jagannath S et al (2006) Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24:3113\u20133120","journal-title":"J Clin Oncol"},{"key":"134_CR110","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.1182\/blood-2005-03-1173","volume":"106","author":"S. Lonial","year":"2005","unstructured":"Lonial S, Waller EK, Richardson PG et al (2005) Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 106:3777\u20133784","journal-title":"Blood"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-007-0134-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-007-0134-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-007-0134-y.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-007-0134-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T19:55:36Z","timestamp":1630439736000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-007-0134-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":110,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["134"],"URL":"https:\/\/doi.org\/10.1007\/s10238-007-0134-y","relation":{},"ISSN":["1591-8890","1591-9528"],"issn-type":[{"value":"1591-8890","type":"print"},{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9]]},"assertion":[{"value":"20 July 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2007","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2007","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"83"}}